Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure

International Heart Journal

Volumn 55, Issue 6, 2014, Pages 533-538

  Sato, Eiichi ^a,b   Nakamura, Tsukasa ^a,b   Amaha, Mayuko ^b   Nomura, Mayumi ^b   Matsumura, Daisuke ^b   Yamagishi, Hidetsugu ^a   Ono, Yuko ^a   Ueda, Yoshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Shinmatsudo Central General Hospital   (Japan)

Author keywords

Aquaporin 2; Histopathological findings

Indexed keywords

ALBUMIN; AQUAPORIN 2; BRAIN NATRIURETIC PEPTIDE; CREATININE; SODIUM; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFICACY; EDEMA; FEMALE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; URINE VOLUME; COMPLICATION; DIABETIC NEPHROPATHIES; KIDNEY; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 2; BENZAZEPINES; DIABETIC NEPHROPATHIES; FEMALE; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; RETROSPECTIVE STUDIES;

EID: 84924804394     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-190     Document Type: Article

References (23)

1. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.
2. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288-94.
3. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebocontrolled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: S33-45.
4. Semba H, Kinugawa K, Takeda N, et al. Preliminary report of tolvaptan treatment in Japanese patients with heart failure. Int Heart J 2012; 53: 72-4.
5. Dohi K, Watanabe K, Ito M. Urine osmolality-guided tolvaptan therapy in decompensated heart failure. Circ J 2013; 77: 313-4.
6. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-8.
7. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders andchronic kidney disease. Circ J 2013; 77: 397-404.
8. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260-9.
9. Gheorghiade M, Gattis WA, O’Connor CM, et al; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.
10. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 2013; 17: 834-8.
11. Iwahori T, Esaki M, Hinoue H, Esaki S, Esaki Y. Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis. Clin Exp Nephrol (in press)
12. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-63.
13. Toka HR, Al-Romaih K, Koshy JM, et al. Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria. J Am Soc Nephrol 2012; 23: 1879-90.
14. Imamura T, Kinugawa K, Kato N, et al. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality. Int Heart J 2013; 54: 115-8.
15. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-12.
16. Noda Y. Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders. Clin Exp Nephrol (in press)
17. Brown D, Bouley R, Păunescu TG, Breton S, Lu HA. New insights into the dynamic regulation of water and acid-base balance by renal epithelial cells. Am J Physiol Cell Physiol 2012; 302: C1421-33. (Review)
18. Kwon TH, Frøkiaer J, Knepper MA, Nielsen S. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 1998; 275: F724-41.
19. Bedford JJ, Leader JP, Walker RJ. Aquaporin expression in normal human kidney and in renal disease. J Am Soc Nephrol 2003; 14: 2581-7.
20. Imamura T, Kinugawa K, Fujino T, et al. Increased Urine Aquaporin-2 Relative to Plasma Vasopressin Is a Novel Marker of Response to Tolvaptan in Patients With Decompensated Heart Failure. Circ J (in press)
21. Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest 1995; 96: 378-85.
22. Yasuoka Y, Kobayashi M, Sato Y, et al. Decreased expression of aquaporin 2 in the collecting duct of mice lacking the vasopressin V1a receptor. Clin Exp Nephrol 2013; 17: 183-90.
23. Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol 2014; 29: 915-7.